This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease
Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year. Mortality at 1 year was 30%, and the stroke incidence was 2.1%. New permanent pacemaker need was 27%. The 1-year mortality appears increased compared to patients without ESRD.